Whitman-Walker Clinic — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$2,152	2
2023	Research	$4,853	1
2021	Research	$23,742	2
2020	Research	$5,400	1
2019	Research	$43,500	16

Breakdown

Who paid Research payments · program years 2019–2024

Janssen Research & Development, LLC $43,358 15 payments
Merck Sharp & Dohme Corporation $24,034 3 payments
ViiV Healthcare Company $11,255 3 payments
GlaxoSmithKline, LLC. $1,000 1 payment

Studies the money was for Research payments · program years 2019–2024

A Phase 3, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed-dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-nave Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Receiving Care in a Test and Treat Model of Care $22,536 10 payments
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral-Activity, and Pharmacokinetics of MK 8591 Given in Combination with Doravirine DOR and Lamivudine 3TC in HIV-1-Infected Treatment-Na Adults $21,882 1 payment
A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects $18,962 4 payments
A Phase 4, Randomized, Open-Label, Three-Arm Study to Evaluate Impleme $4,853 1 payment
A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, No $3,282 1 payment
A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority $3,121 1 payment
A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine MK-1439 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA or EPZICOM ,KIVEXA , in Treatment-Na ve HIV-1 Infected Subjects $2,152 2 payments
Study to Evaluate Efficacy and Safety of Darunavir Cobicistat Emtricitabine Tenofovir Alafenamide DCFTAF Regimen Versus Boosted Protease Inhibitor bPI Along With Emtricitabine Tenofovir Disoproxil Fumarate FTCTDF Regimen in Virologically Suppressed HIV1 In $1,860 1 payment
A Phase 2A, Multicenter, Randomized, Parallel, Double-Blind, Dose Rang $1,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.